Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Saved in:
| Title: | Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. |
|---|---|
| Authors: | Goldberg, Sarah B1 (AUTHOR) sarah.goldberg@yale.edu, Schalper, Kurt A2 (AUTHOR), Gettinger, Scott N1 (AUTHOR), Mahajan, Amit3 (AUTHOR), Herbst, Roy S1 (AUTHOR), Chiang, Anne C1 (AUTHOR), Lilenbaum, Rogerio1 (AUTHOR), Wilson, Frederick H1 (AUTHOR), Omay, Sacit Bulent4 (AUTHOR), Yu, James B5 (AUTHOR), Jilaveanu, Lucia1 (AUTHOR), Tran, Thuy1 (AUTHOR), Pavlik, Kira1 (AUTHOR), Rowen, Elin1 (AUTHOR), Gerrish, Heather1 (AUTHOR), Komlo, Annette1 (AUTHOR), Gupta, Richa1 (AUTHOR), Wyatt, Hailey1 (AUTHOR), Ribeiro, Matthew1 (AUTHOR), Kluger, Yuval2 (AUTHOR) |
| Source: | Lancet Oncology. May2020, Vol. 21 Issue 5, p655-663. 9p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
